Condition: Psoriasis Vulgaris · Sponsor: University Hospital, Ghent
Biologics, such as brodalumab, are currently the most effective treatment option for patients with moderate-to-severe psoriasis. But they are costly for health care systems and prescribed according to a 'one dose fits all' dosing regimen, leading to potential over- and undertreatment. Within this study we aim to investigate the predictive value of early serum trough levels of brodalumab and determine the therapeutic window of brodalumab in psoriasis patients.
This description comes directly from the study's public registry record.
Jo Lambert, Prof. · 09 332 22 87 · jo.lambert@uzgent.be
Lynda Grine, Dr. · 09 332 22 87 · lynda.grine@uzgent.be
Always discuss trial participation with your own doctor first.
| AZ Maria Middelares | Ghent, Oost-Vlaanderen, Belgium | Not Yet Recruiting |
| AZ Sint-Lucas | Ghent, Oost-Vlaanderen, Belgium | Not Yet Recruiting |
| University Hospital of Ghent | Ghent, Oost-Vlaanderen, Belgium | Recruiting |
| Private Practice Dermatology | Maldegem, Oost-Vlaanderen, Belgium | Not Yet Recruiting |
| University Hospital | Leuven, Vlaams-Brabant, Belgium | Not Yet Recruiting |
| AZ Sint-Jan | Bruges, West-Vlaanderen, Belgium | Not Yet Recruiting |
| AZ Delta Rembert | Torhout, West-Vlaanderen, Belgium | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04080635